Liminatus Pharma, Inc. (LIMN): Total Liabilities
$10.33M
As of 2025-12-31
$3.10M
As of 2026-06-30
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $10.33M | -58.3% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $24.75M | n/a | 2026-03-31, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | 2025-12-31 | $10.33M | -58.3% |
| Adaptin Bio, Inc. (APTN) | 2025-12-31 | $2.11M | -51.4% |
| Brainstorm Cell Therapeutics Inc. (BCLI) | 2025-12-31 | $11.01M | +14.7% |
| Abpro Holdings, Inc. (ABPO) | 2024-12-31 | $19.61M | +21.1% |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | $2.95M | -10.5% |
| Zivo Bioscience, Inc. (ZIVO) | 2024-12-31 | $2.16M | -21.9% |
| Estrella Immunopharma, Inc. (ESLA) | 2025-12-31 | $13.54M | +351.9% |
| BioCardia, Inc. (BCDA) | 2025-12-31 | $2.52M | -12.8% |
| Cero Therapeutics Holdings, Inc. (CERO) | 2025-12-31 | $9.09M | +12.2% |
Compare LIMN, APTN, BCLI, ABPO side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗